[1] COLLABORATORS GBDLROS，FEIGIN V L，

NGUYEN G，et al. Global，regional，and countryspecific

lifetime risks of stroke，1990 and 2016[J]. N

Engl J Med，2018，379（25）：2429-2437.

[2] MALIK R，CHAUHAN G，TRAYLOR M，et al.

Multiancestry genome-wide association study of 520，

000 subjects identifies 32 loci associated with stroke

and stroke subtypes[J]. Nat Genet，2018，50（4）：

524-537.

[3] National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[4] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4.5 hours after

acute ischemic stroke[J]. N Engl J Med，2008，359

（13）：1317-1329.

[5] BERKHEMER O A，FRANSEN P S，BEUMER D，

et al. A randomized trial of intraarterial treatment

for acute ischemic stroke[J]. N Engl J Med，2015，372

（1）：11-20.

[6] CAMPBELL B C，MITCHELL P J，KLEINIG T J，

et al. Endovascular therapy for ischemic stroke with

perfusion-imaging selection[J]. N Engl J Med，2015，

372（11），1009-1018.

[7] GOYAL M，DEMCHUK A M，MENON B K，et

al. Randomized assessment of rapid endovascular

treatment of ischemic stroke[J]. N Engl J Med，2015，

372（11）：1019-1030.

[8] JOVIN T G，CHAMORRO A，COBO E，et al.

Thrombectomy within 8 hours after symptom onset

in ischemic stroke[J]. N Engl J Med，2015，372（24）：

2296-2306.

[9] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，

et al. Thrombectomy 6 to 24 hours after stroke with

a mismatch between deficit and infarct[J]. N Engl J

Med，2018，378（1）：11-21.

[10] ALBERS G W，MARKS M P，KEMP S，et al.

Thrombectomy for stroke at 6 to 16 hours with

selection by perfusion imaging[J]. N Engl J Med，

2018，378（8）：708-718.

[11] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. 2018 guidelines for the early management

of patients with acute ischemic stroke：A guideline

for healthcare professionals from the American

Heart Association/American Stroke Association[J/

OL]. Stroke，2018，49（3）：e46-e110. https：//doi.

org/10.1161/STR.0000000000000158.

[12] THOMALLA G，SIMONSEN C Z，BOUTITIE

F，et al. Mri-guided thrombolysis for stroke with

unknown time of onset[J]. N Engl J Med，2018，379

（7）：611-622.

[13] CAMPBELL B C V，MITCHELL P J，CHURILOV

L，et al. Tenecteplase versus alteplase before

thrombectomy for ischemic stroke[J]. N Engl J Med，

2018，378（17）：1573-1582.

[14] HUANG X，CHERIPELLI B K，LLOYD S M，et al.

Alteplase versus tenecteplase for thrombolysis after

ischaemic stroke（ATTEST）：a phase 2，randomised，

open-label，blinded endpoint study[J]. Lancet Neurol，

2015，14（4）：368-376.

[15] LOGALLO N，NOVOTNY V，ASSMUS J，et

al. Tenecteplase versus alteplase for management

of acute ischaemic stroke（nor-test）：A phase 3，

randomised，open-label，blinded endpoint trial[J].

Lancet Neurol，2017，16（10）：781-788.

[16] KHATRI P，KLEINDORFER D O，DEVLIN T，

et al. Effect of alteplase vs aspirin on functional

outcome for patients with acute ischemic stroke and

minor nondisabling neurologic deficits：the PRISMS

randomized clinical trial[J]. JAMA，2018，320（2）：

156-166.

[17] POWERS W J. Intravenous alteplase for mild

nondisabling acute ischemic stroke：A bridge too

far?[J]. JAMA，2018，320（2）：141-143. [18] JOHNSTON S C，EASTON J D，FARRANT M，et

al. Clopidogrel and aspirin in acute ischemic stroke

and high-risk TIA[J]. N Engl J Med，2018，379（3）：

215-225.

[19] WANG Y，WANG Y，ZHAO X，et al. Clopidogrel

with aspirin in acute minor stroke or transient

ischemic attack[J]. N Engl J Med，2013，369（1）：

11-19.

[20] PAN Y，JING J，CHEN W，et al. Risks and benefits

of clopidogrel-aspirin in minor stroke or TIA：Time

course analysis of CHANCE[J]. Neurology，2017，88

（20）：1906-1911.

[21] KRISHNAN K，BERIDZE M，CHRISTENSEN H，

et al. Safety and efficacy of intensive vs . Guideline

antiplatelet therapy in high-risk patients with

recent ischemic stroke or transient ischemic attack：

Rationale and design of the triple antiplatelets

for reducing dependency after ischaemic stroke

（TARDIS）trial（ISRCTN47823388）[J]. Int J Stroke，

2015，10（7）：1159-1165.

[22] BATH P M，WOODHOUSE L J，APPLETON J P，

et al. Antiplatelet therapy with aspirin，clopidogrel，

and dipyridamole versus clopidogrel alone or aspirin

and dipyridamole in patients with acute cerebral

ischaemia（TARDIS）：A randomised，openlabel，

phase 3 superiority trial[J]. Lancet，2018，391

（10 123）：850-859.

[23] AMARENCO P. Learning from TARDIS：Time for

more focused trials in stroke prevention[J]. Lancet，

2018，391（10 123）：819-821.

[24] HAO Q，TAMPI M，O'DONNELL M，et al.

Clopidogrel plus aspirin versus aspirin alone for

acute minor ischaemic stroke or high risk transient

ischaemic attack：Systematic review and metaanalysis[

J/OL]. BMJ，2018，363：k5108. https：//doi.

org/10.1136/bmj.k5108.

[25] PRASAD K，SIEMIENIUK R，HAO Q，et al. Dual

antiplatelet therapy with aspirin and clopidogrel for

acute high risk transient ischaemic attack and minor

ischaemic stroke：A clinical practice guideline[J/OL].

BMJ，2018，363：k5130. https：//doi.org/10.1136/bmj.

k5130.

[26] KIM J T，PARK M S，CHOI K H，et al. Comparative

effectiveness of aspirin and clopidogrel versus

aspirin in acute minor stroke or transient ischemic

attack[J/OL]. Stroke，2018，50（1）：101-109. https：//

doi.org/10.1161/STROKEAHA.118.022691.

[27] HART R G，DIENER H C，COUTTS S B，et al.

Embolic strokes of undetermined source：The case

for a new clinical construct[J]. Lancet Neurol，2014，

13（4）：429-438.

[28] HART R G，SHARMA M，MUNDL H，et al.

Rivaroxaban for stroke prevention after embolic

stroke of undetermined source[J]. N Engl J Med，

2018，378（23）：2191-2201.

[29] KASNER SE，SWAMINATHAN B，LAVADOS

P，et al. Rivaroxaban or aspirin for patent foramen

ovale and embolic stroke of undetermined source：A

prespecified subgroup analysis from the NAVIGATE

ESUS trial[J]. Lancet Neurol，2018，17（12）：1053-

1060.

[30] SPRIGG N，FLAHERTY K，APPLETON J P，et

al. Tranexamic acid for hyperacute primary Intra

Cerebral Haemorrhage（TICH-2）：an international

randomised，placebo-controlled，phase 3 superiority

trial[J]. Lancet，2018，391（10 135）：2107-2115.

[31] MEAD G，HACKETT M L，LUNDSTRÖM E，et

al. The FOCUS，AFFINITY and EFFECTS trials

studying the effect（s）of fluoxetine in patients with a

recent stroke：a study protocol for three multicentre

randomised controlled trials[J/OL]. Trials，2015，16：

369. https：//doi.org/10.1186/s13063-015-0864-1.

[32] DENNIS M，MEAD G，FORBES J，et al. Effects of

fluoxetine on functional outcomes after acute stroke

（FOCUS）：a pragmatic，double-blind，randomised，

controlled trial[J]. Lancet，2018，393（10 168）：265-

274.

[33] WANGQIN R，LASKOWITZ D T，WANG Y L，et

al. International comparison of patient characteristics

and quality of care for ischemic stroke：analysis of

the china national stroke registry and the american

heart association get with the guidelines--stroke

program[J/OL]. J Am Heart Assoc，2018，7（20）：

e010623. https：//doi.org/10.1161/JAHA.118.010623.

[34] LI Z X，PANDIAN J，SYLAJA P N，et al. Quality of

care for ischemic stroke in China vs India：findings

from national clinical registries[J/OL]. Neurology，

2018，91（14）：e1348-e1354. https：//doi.org/10.1212/

WNL.0000000000006291.

[35] WANG Y，LI Z，ZHAO X，et al. Evidence-Based

performance measures and outcomes in patients with

acute ischemic stroke[J/OL]. Circ Cardiovasc Qual

Outcomes，2018，11（12）：e001968. https：//doi.

org/10.1161/CIRCOUTCOMES.115.001968.

[36] WANG Y，LI Z，ZHAO X，et al. Effect of a

multifaceted quality improvement intervention

on hospital personnel adherence to performance

measures in patients with acute ischemic stroke in

china[J]. JAMA，2018，320（3）：245-254.